QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study

QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study

Abstract First-line chemoimmunotherapy (with or without bevacizumab) has improved outcomes in advanced non-small cell lung cancer (NSCLC). Here, this open-label, multi-cohort phase II study (NCT05329025) was done to investigate the safety and efficacy of QL1706 (a single bifunctional MabPair product...

Full description

Bibliographic Details
Main Authors: Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Hongyun Zhao, Ningning Zhou, Yaxiong Zhang, Likun Chen, Ting Zhou, Gang Chen, Ting Wu, Lu Lu, Shilin Xue, Xiaoyan Kang, Li Zhang, Wenfeng Fang
Format: Article
Language:English
Published: Nature Publishing Group 2024-01-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-023-01731-x

Internet

https://doi.org/10.1038/s41392-023-01731-x

Similar Items